IP Library › Granted Patent US 8,334,316
Granted Patent B2
US 8,334,316 · App. 12/368,206 · Granted Dec 18, 2012

Substituted organosulfur compounds and methods of using thereof

Assignee: ACEA Biosciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,334,316
App. No.
12/368,206
Granted
Dec 18, 2012
Kind
B2
Abstract

The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions.

Claims (35)

1. A compound having the formula:

wherein A and B are the same,

A is pyridine, pyridazine, pyrimidine, pyrazine, triazine, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, pyrazole, imidazole, thiazole, oxazole, pyrrole, thiophene indolizine, indole, isoindole, indoline, benzofuran, benzothiophene, indazole, benzimidazole, benzthiazole, purine, quinoxaline, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridine, pteridine, acridine, phenazine, phenothiazine, indene, or naphthalene, each of which is optionally substituted with one or more heteroatoms selected from O, N and S; halo; or C 1-10 alkyl, C 3-10 cyclic alkyl, C 2-10 alkenyl or alkynyl, aryl, or heterocycle, each optionally containing one or more heteroatoms;

B is selected from pyridine, pyridazine, pyrimidine, pyrazine, triazine, isoxazole, isothiazole, oxadiazole, triazole, thiadiazole, pyrazole, imidazole, thiazole, oxazole, pyrrole, thiophene indolizine, indole, isoindole, indoline, benzofuran, benzothiophene, indazole, benzimidazole, benzthiazole, purine, quinoxaline, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridine, pteridine, acridine, phenazine, phenothiazine, and indene, each of which is optionally substituted with one or more heteroatoms selected from O, N and S; halo; or C 1-10 alkyl, C 3-10 cyclic alkyl, C 2-10 alkenyl or alkynyl, aryl, or heterocycle, each optionally containing one or more heteroatoms;

each S is optionally in the form of an oxide;

each R is H, halogen, carboxyl, cyano, amino, amido, an inorganic substituent, SR 1 , OR 1 or R 1 , wherein each R 1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, a carbocyclic ring or a heterocyclic ring, each of which is optionally substituted and may contain a heteroatom;

n is 1;

p is 1;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R is independently H, halo, OR 1 , SR 1 , CO 2 R 1 , CONR 1 2 , C═O, CN, CF 3 , OCF 3 , NO 2 , NR 1 R 1 , OCOR 1 ; or R is C 1-10 alkyl, C 3-10 cyclic alkyl, C 2-10 alkenyl, C 2-10 alkynyl, an aryl, heteroaryl, a carbocyclic ring or a heterocyclic ring, each of which may contain a heteroatom.

3. The compound of claim 1 , wherein A and B are independently selected from pyridine, pyridazine, pyrimidine, pyrazine, triazine, isoxazole, isothiazole, oxadiazole, [1,2,4]oxadiazole, triazole, thiadiazole, pyrazole, imidazole, thiazole, oxazole, benzoxazole, pyrrole, thiophene, indolizine, indole, isoindole, indoline, benzofuran, benzothiophene, indazole, benzimidazole, benzthiazole, purine, quinoxaline, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, naphthyridine, pteridine, acridine, phenazine, phenothiazine, indene, benzoxadiazol, and benzo[1,2,5]-oxadiazole.

4. The compound of claim 1 , wherein A and B are independently selected from pyridine, pyridazine, pyrimidine, pyrazine, isoxazole, isothiazole, oxadiazole, thiazole, oxazole, benzoxazole, thiophene, indolizine, benzofuran, benzothiophene, and benzo[1,2,5]-oxadiazole.

5. The compound of claim 1 , wherein said compound has the formula (7)

wherein Ar is an optionally substituted thiophene, benzothiophene, pyridine or pyrazine.

6. The compound of claim 1 , wherein each R is H.

7. A method for ameliorating or treating neuroblastoma, comprising administering to a subject in need thereof an effective amount of a compound in claim 1 or a pharmaceutical composition thereof and optionally with an antiproliferative agent, whereby said neuroblastoma is ameliorated or treated.

8. A method for treating or ameliorating a cancer selected from the group consisting of leukemia, lymphoma, lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, head-neck cancer, pancreatic cancer, and renal cancer, comprising administering to a subject in need thereof an effective amount of the compound of claim 1 ,

or a pharmaceutical composition thereof, and optionally with an antiproliferative agent;

whereby said cancer in said subject is ameliorated or treated.

9. The method of claim 8 , wherein said subject is a human.

10. The method of claim 8 , wherein said compound is a compound according to claim 2 .

11. The method of claim 10 , wherein said compound is a compound according to claim 3 .

12. The method of claim 8 , wherein said compound is a compound according to claim 5 .

13. A method for ameliorating or treating restenosis, comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutical composition thereof, whereby restenosis in said subject is ameliorated or treated.

14. The method of claim 13 , wherein said restenosis is associated with neointimal hyperplasia.

15. The method of claim 13 , wherein said administering step is oral or parental administration, or administration via a stent.

16. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable excipient.

17. A method for preparing a compound of claim 1 , comprising:

a) contacting N-trimethylsilyl imidazole with sulfur dichloride in a halogenated solvent to provide diimidazolylsulfide; and

b) contacting said diimidazolylsulfide with mercaptan.

18. A method for preparing a composition comprising a compound of claim 1 , comprising:

a) dissolving a compound of claim 1 in a water-soluble organic solvent, a non-ionic solvent, a water-soluble lipid, a cyclodextrin, a vitamin, a fatty acid, a fatty acid ester, a phospholipid, or a combination thereof, to provide a solution; and

b) adding saline or a buffer containing 1-10% carbohydrate solution.

19. The method of claim 7 , wherein the subject is a human.

20. The method of claim 13 , wherein the subject is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2018
From: ACEA BIOSCIENCES, INC.
To: ACEA THERAPEUTICS, INC.
Reel/Frame 047492/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2009
From: XU, XIAO; AN, HAOYUN; WANG, XIAOBO
To: ACEA BIOSCIENCES, INC.
Reel/Frame 022252/0761 →
Continuity (3)
Division 11110203 · Apr 20, 2005
Provisional Application 60564151 · Apr 20, 2004
Related Publication 20090192146A1 · Jul 30, 2009